COVID‐19 outcomes in patients with autoimmune blistering disease

Dear Editor, Autoimmune blistering diseases (AIBD) are often treated with immunosuppressive medications, including rituximab, yet the implications of these approaches during the COVID‐19 pandemic are not fully understood. COVID‐19 outcome studies in patients with AIBD are limited by small sample sizes and interpretation complicated by advanced age and comorbidities common in this population. On the one hand, although a diagnosis of bullous pemphigoid (BP) alone may present a higher risk of death from COVID‐19 disease,1 a review of published case reports2 and a population‐based cohort study1 of patients with AIBD who had confirmed SARS‐CoV‐2 infection (16 and 36 patients, respectively), suggested that immunomodulatory treatments do not increase risks of contracting COVID‐19 or of poor outcomes. On the other hand, a study of 17 patients with AIBD who had documented SARS‐CoV‐2 infection found increased risk of hospitalization with more recent rituximab treatment,3 suggesting that the risks of treatment, especially with rituximab, deserve further investigation. Indeed, an increased risk of death has been observed among rheumatology patients on rituximab.4–6 To provide clarity on the risk of treating AIBD with immunosuppressive therapies, particularly rituximab, during the pandemic, we assembled and analysed outcomes in a cohort treated in our US institution. We performed an institutional review board‐approved retrospective search of the electronic health record for patients with diagnoses of pemphigoid or pemphigus and conducted a chart review of those who had SARS‐CoV‐2 infection confirmed by polymerase chain reaction between 1 February 2020 and 1 July 2020. Additionally, we contacted patients with AIBD followed in our academic tertiary care clinic and reviewed the history of those diagnosed with COVID‐19. Of 19 patients with AIBD identified, 11 patients had BP, one had ocular cicatricial pemphigoid, four had pemphigus vulgaris (PV), and three had pemphigus foliaceus. Clinical findings are summarized in Table 1. Characteristics and COVID‐19 outcomes of patients with autoimmune blistering diseases (AIBD) who contracted COVID‐19 BP, bullous pemphigoid; COPD, chronic obstructive pulmonary disease; DCN, doxycycline; F, female; M, male; MCN, minocycline; MMF, mycophenolate mofetil; MTX, methotrexate; OCP, ocular cicatricial pemphigoid; PF, pemphigus foliaceous; pred, prednisone; PV, pemphigus vulgaris; RTX, rituximab; TCS, topical corticosteroids. aTreated with azithromycin in her skilled nursing facility at the beginning of the pandemic; btreated with remdesivir, convalescent plasma, admitted to intensive care and ventilated; cmanaged as high risk with decadron and bamlanivimab owing to recent rituximab infusion; dadmitted to intensive care; ehospital course complicated by embolic stroke, deep vein thrombosis, pulmonary embolism; frecovered but BP flared, entered hospice care months later; gtreated with tocilizumab and supplemental oxygen. Characteristics and COVID‐19 outcomes of patients with autoimmune blistering diseases (AIBD) who contracted COVID‐19 BP, bullous pemphigoid; COPD, chronic obstructive pulmonary disease; DCN, doxycycline; F, female; M, male; MCN, minocycline; MMF, mycophenolate mofetil; MTX, methotrexate; OCP, ocular cicatricial pemphigoid; PF, pemphigus foliaceous; pred, prednisone; PV, pemphigus vulgaris; RTX, rituximab; TCS, topical corticosteroids. aTreated with azithromycin in her skilled nursing facility at the beginning of the pandemic; btreated with remdesivir, convalescent plasma, admitted to intensive care and ventilated; cmanaged as high risk with decadron and bamlanivimab owing to recent rituximab infusion; dadmitted to intensive care; ehospital course complicated by embolic stroke, deep vein thrombosis, pulmonary embolism; frecovered but BP flared, entered hospice care months later; gtreated with tocilizumab and supplemental oxygen. In our cohort, the only patients who succumbed to COVID‐19 were treated with rituximab. Although three patients who received rituximab ≥ 6 months prior recovered without intervention, two of three who received rituximab ≤ 5 months prior to COVID‐19 diagnosis died. One was a 74‐year‐old man with PV and hypertension on prednisone 40 mg daily who received rituximab 2 months prior to COVID‐19 diagnosis; he was treated with remdesivir, convalescent plasma and mechanical ventilation. The other was an 82‐year‐old woman with BP, dementia, chronic obstructive lung disease and hypertension, all of which are independent risk factors for poor outcome, who received rituximab 4 months prior to COVID‐19 diagnosis. She was treated with azithromycin at the beginning of the pandemic in her skilled nursing facility before succumbing. A 65‐year‐old man with PV and obesity on mycophenolate mofetil who received rituximab 5 months prior was treated with decadron and bamlanivimab and recovered without hospitalization. Altogether, six patients were treated with rituximab, three with mycophenolate mofetil, five with methotrexate (each alone or in combination with prednisone), and five with topical steroids alone or in combination with tetracycline antibiotics. All five patients treated with topical corticosteroid/tetracycline recovered. Two required hospitalization – a 99‐year‐old woman who had a BP flare after recovery and entered hospice care soon thereafter and a 102‐year‐old woman with BP treated with tocilizumab and supplemental oxygen. The five patients in the methotrexate group recovered at home. The three patients treated with mycophenolate mofetil recovered, one after intensive care unit admission, tocilizumab, high‐dose steroids and ventilation, and one after a hospital course complicated by embolic stroke, deep vein thrombosis and pulmonary embolism. The recovery of 17 of 19 patients with AIBD who had documented SARS‐CoV‐2 infection in our single institution cohort, despite advanced age and comorbidities, is reassuring. The two deaths were in individuals treated with rituximab < 6 months before infection, suggesting that recent rituximab therapy may increase risk of poor outcomes. These findings complement observations of decreased hospitalization rates of infected patients with AIBD with increasing intervals post rituximab3 and a 4·04‐fold increase in death among rheumatology patients on rituximab,4 and likely reflect the kinetics of B cell reconstitution following depletion.7 Thus, our data provide specific rational supporting expert guidelines to weigh the risks of rituximab relative to other immunosuppressive therapies for AIBD during this pandemic.8 Although larger datasets are needed, our observations suggest that patients on rituximab be counselled about the increased risks for poor COVID‐19 outcomes. Patients should␣be vaccinated prior to therapy when possible, and dermatologists should consider confirming response with SARS‐CoV‐2 spike protein IgG serologies. Finally, the observations in this cohort, although small, provide rationale for the immediate use of COVID‐19 monoclonal antibodies such as bamlanivimab, etesevimab, casirivimab and imdevimab after SARS‐CoV‐2 detection in dermatology patients treated with rituximab in the previous 6 months. Erica Hwang: Conceptualization (supporting); Data curation (supporting); Formal analysis (supporting); Funding acquisition (supporting); Investigation (supporting); Methodology (supporting); Project administration (supporting); Resources (supporting); Software (equal); Supervision (supporting); Validation (supporting); Visualization (equal); Writing‐original draft (lead); Writing‐review & editing (supporting). Mary M Tomayko: Conceptualization (lead); Data curation (lead); Formal analysis (lead); Funding acquisition (lead); Investigation (lead); Methodology (equal); Project administration (equal); Resources (lead); Software (equal); Supervision (lead); Validation (lead); Visualization (equal); Writing‐original draft (supporting); Writing‐review & editing (lead). Funding sources: E.H. was supported by NIH/NHLBI training grant T35HL007649. Conflicts of interest: the authors declare they have no conflicts of interest. Data availability: the data that support the findings of this study are available on request from the corresponding author. The data are not publicly available owing to privacy or ethical restrictions.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.